95 Antibody-Drug Conjugate (ADC) CRO and CDMO vendors

What does it take to develop and manufacture an Antibody-Drug Conjugate (ADC) drug?

An ADC is three molecules pretending to be one. You have a monoclonal antibody that finds the tumor, a cytotoxic payload potent enough that a few molecules per cell can kill it, and a linker that holds the two together in circulation and then releases the payload where it should. Each part is a separate discipline, and the hard part of ADC work is that they have to behave as a single product through manufacturing, release testing, and a regulatory filing. A generalist biologics shop can make the antibody. A small-molecule house can make the payload. Far fewer can do the conjugation step in between and control it well enough to ship clinical material.

On the discovery and preclinical side the questions are about payload class (auristatin, maytansinoid, topoisomerase inhibitor, the newer immune-stimulating payloads), linker chemistry (cleavable versus non-cleavable, and how stable it is in plasma), and the conjugation method itself. Lysine and interchain-cysteine conjugation are the workhorses and give you a heterogeneous mixture; site-specific approaches (engineered cysteines, enzymatic tags, click chemistry) give a tighter, more defined product but add development work. The number that ties all of this together is DAR, the drug-to-antibody ratio, plus its distribution. DAR drives potency, pharmacokinetics, and aggregation, so analytical control of DAR is not a nice-to-have, it is the product specification.

The CMC and manufacturing side is where specialist ADC CDMOs separate from generalists, and the reason is containment. ADC payloads are high-potency APIs (HPAPI), often with occupational exposure limits in the nanogram range, so the conjugation suite needs isolators, closed processing, and a containment and industrial-hygiene program that an ordinary biologics or small-molecule plant does not have. On top of that you need the payload-linker synthesis, the bioconjugation step, purification (TFF, chromatography) to strip unconjugated payload, and a sterile fill-finish that can handle a cytotoxic drug product. Just as telling is the analytical package: DAR by HIC and mass spec, free-drug and residual-solvent assays, aggregate and charge-variant profiling, and a potency assay that reflects the conjugate, not just the naked antibody. A vendor who can run the chemistry but cannot characterize the molecule to a regulator's satisfaction will stall you at the IND.

How do you choose a CRO or CDMO for Antibody-Drug Conjugate (ADC)?

The first filter is whether the vendor actually does conjugation, not just one of the three pieces around it. Plenty of capable antibody manufacturers and plenty of capable HPAPI chemistry houses will tell you they support ADCs because they own one part of the chain. What you want, especially early, is either a single CDMO that runs payload-linker, conjugation, purification, and fill-finish under one roof, or a small set of partners with a clear interface and a track record of working together. Each handoff of cytotoxic material between sites is a containment, shipping, and analytical-comparability problem, so fewer seams is usually fewer delays.

Use the checklist below when you put two or three vendors against the same written scope and the same target DAR and timeline.

• Relevant platform and track record: confirm they have run your conjugation chemistry (lysine, interchain-cysteine, or site-specific) and a payload of your class, ideally on a molecule that reached IND or beyond, not just a feasibility batch.
• HPAPI containment and GxP: isolator-based or closed conjugation suites, a defined occupational exposure band for your payload, and the right quality system for the phase you are at (GMP for clinical supply, documented GLP feeding the tox package).
• Analytical capability for this modality: in-house DAR by HIC and intact-mass, free-drug and residual-payload methods, aggregate and charge-variant analysis, and a conjugate potency assay. Ask to see method development data, not just a capability list.
• Capacity and scale: realistic queue for an isolator suite (containment capacity is the bottleneck in this industry, not stainless steel), and a credible path from grams of clinical material to a commercial scale you can name.
• Regulatory experience: prior INDs or BLAs with an ADC component, comfort with FDA and EMA expectations on DAR specification and comparability, and experience writing the conjugation and characterization sections of a regulatory filing.
• IP and confidentiality: a CDA before you disclose the linker or payload, clear ownership of process and analytical know-how generated on your program, and clarity on whether any of their conjugation or linker technology is licensed or carries downstream royalties.